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Purpose: The purpose of this study was to evaluate
the pharmacokinetics (PK) and 24-hour analgesic
effectiveness of once-daily, single-entity, extended-
release hydrocodone (HYD) with abuse-deterrent
properties.
Methods: Four studies were included. Three open-
label PK studies had the following designs: single-dose,
5-treatment, 4-period, crossover, dose-proportionality
study; HYD 120 mg for 5 days (steady-state study 1);
2-treatment, 2-period, multiple-dose crossover study
assessing the relative bioavailability of HYD 30 mg
and hydrocodone 7.5 mg/ibuprofen 200 mg adminis-
tered every 6 hours (steady-state study 2). A long-term,
open-label study assessed the safety and effectiveness of
HYD 20 to 120 mg in patients during a 52-week
maintenance period.
Findings: Thirty-one, 25, and 22 healthy subjects
completed the dose-proportionality study, steady-state
study 1, and steady-state study 2, respectively, while
410 patients with moderate to severe chronic non-
malignant and non-neuropathic pain completed the
long-term effectiveness study. Mean systemic exposure
and peak plasma concentration were dose propor-
tional after administration of single doses of HYD 20
to 120 mg. Pharmacokinetic proﬁles were comparable
at day 1 and day 5 after administration of HYD 120
mg once daily. Once-daily HYD 30 mg was associated
with lower-ﬂuctuating plasma hydrocodone concen-
trations compared with immediate-release hydroco-
done 7.5 mg/ibuprofen 200 mg administered every 6
hours. In the long-term study, pain control was
consistent over the 24-hour dosing interval.
Implications: Once-daily HYD exhibits linear, dose-
proportional PK properties and is associated with
a lower variability in plasma hydrocodone concen-
trations when compared with an immediate-release hy-
drocodone combination product. Notably, analgesia302provided by HYD is sustained during the 24-hour dosing
interval. ClinicalTrials.gov identiﬁer: NCT01400139
(Study 4). (Clin Ther. 2016;38:302–314) & 2016 The
Authors. Published by Elsevier HS Journals, Inc.
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pharmacokinetics.INTRODUCTION
More than 100 million Americans experience chronic
malignant and nonmalignant pain, and the annual cost
of pain care in the United States, including reduced
productivity and wages, is estimated to be between US
$560 billion and $635 billion.1 Immediate-release (IR)
hydrocodone combination products are generally con-
sidered by clinicians to be safe and effective for the
treatment of pain, and they are among the most
commonly prescribed analgesics in the United States.2
However, they require frequent dosing (ie, 4–6 times
daily), and their use is associated with a risk for acute
liver injury (including failure) or gastrointestinal
toxicity due to the nonopioid component.3–6
Extended-release (ER) opioid formulations may be
better suited for appropriate chronic pain patients.
Review articles have found that, compared with IR
formulations, oral ER products produce more consis-
tent plasma concentrations and lower peak-to-trough
ﬂuctuations over the dosing interval.7,8 Additionally,
the pharmacokinetic (PK) characteristics of ER pro-
ducts have been found to provide sustained pain relief,
with less frequent dosing, reduced pill burden, andVolume 38 Number 2
R.P. Kapil et al.more stable clinical effects.7–9 Furthermore, a single-
entity ER hydrocodone product may reduce the risks
associated with the nonopioid components of the IR
products, permitting a higher total daily hydrocodone
dose in appropriate patients in whom the beneﬁt/risk
balance justiﬁes such a regimen.
Despite the clinical beneﬁts of prescription opioids,
the use of these medications has the potential for
abuse and misuse. Prescription opioid abuse in the
United States has been increasing in prevalence, affects
multiple aspects of life on personal and societal levels,
and has a great impact on the health care system.10,11
Development of formulations with abuse-deterrent
properties is 1 approach in the effort to reduce the
abuse and misuse of prescription opioids while pre-
serving analgesic beneﬁts for patients.12,13
In November 2014, a single-entity, once-daily, ER
hydrocodone bitartrate tablet* with abuse-deterrent
properties (HYD) was approved in the United States
for the management of nonmalignant pain severe
enough to require daily, around-the-clock, long-term
opioid treatment for which other treatment options
are inadequate.14 HYD tablets do not contain a
nonopioid component (eg, acetaminophen or ibu-
profen) and are formulated in multiple strengths
(20–120 mg). HYD is formulated using a
proprietary ER solid oral dosage formulation†
platform that uses a unique combination of polymer
and processing that confers tablet hardness and
imparts viscosity when dissolved in aqueous solutions.
The HYD clinical development program was de-
signed to assess the PK properties of the targeted 24-
hour proﬁle in healthy subjects, as well as the analgesic
effects over the 24-hour dosing interval. This paper
reports the HYD PK results of 1 dose-proportionality
study and 2 steady-state studies conducted in healthy
subjects, as well as the HYD analgesic effect over the
24-hour dosing interval, examined in a long-term study
in patients with chronic nonmalignant and non-
neuropathic pain. Primary results of the long-term
study have been published15; to facilitate a ready
juxtaposition of PK data and long-term efﬁcacy data
in this article, selected previously reported results from
the long-term study are included here.*Trademark: Hysinglas ER (Purdue Pharma LP, Stamford,
CT).
†Trademark: Resistec™ (Purdue Pharma LP).
February 2016PATIENTS AND METHODS
All 4 study protocols were approved by accredited
institutional review boards at sites in the United States
where the studies were conducted. The studies were
conducted in compliance with the International Con-
ference on Harmonisation E6 Good Clinical Practice
and the US Code of Federal Regulations guidelines.
All subjects provided written informed consent before
entering the studies.
Study Participants
Dose-proportionality and Steady-State Studies 1
and 2
The PK studies enrolled healthy male and female
subjects aged 18 to 50 years with a body weight of 50
to 100 kg (110–220 lb) and a body mass index of 18
to 30 kg/m2. Subjects had to be free of signiﬁcant
abnormal ﬁndings as determined by medical history,
physical examination, clinical laboratory values, vital
signs, and ECG. Subjects were excluded from the
study if they had any clinically signiﬁcant or relevant
neurologic, gastrointestinal, renal, cardiovascular,
hepatic, psychological, metabolic, hematologic, or
allergic reactions, or other major disorder.
Long-Term Effectiveness Study
Eligible patients were 18 years of age or older, with
moderate to severe chronic nonmalignant and non-
neuropathic pain that lasted at least several hours
daily for a minimum of 3 months, and who were
deemed by the investigators to be appropriate candi-
dates for the protocol-speciﬁed (around-the-clock)
HYD therapeutic regimen. Patients included in the
long-term effectiveness study had chronic nonmalig-
nant pain that was either controlled by a stable
analgesic regimen equivalent to 0 to 120 mg/d of
oxycodone (as indicated by an “average pain over the
last 14 days” score of r4 [using an 11-point numeric
rating scale in which 0 ¼ “no pain” and 10 ¼ “pain
as bad as you can imagine”]) or uncontrolled by a
stable analgesic regimen equivalent to 0 to 100 mg/d
of oxycodone (as indicated by an “average pain over
the last 14 days” score ofZ5). Patients were excluded
from enrollment in the long-term study if they had
chronic pain from neuropathic or malignant causes;
ﬁbromyalgia; reﬂex sympathetic dystrophy or causalgia;
diabetic amyotrophy; meningitis; discitis; uncontrolled
gout; pseudogout; psoriatic arthritis; active Lyme disease;
rheumatoid arthritis or other inﬂammatory arthritis;303
‡Trademark: Vicoprofens (AbbVie, North Chicago, IL).
Clinical Therapeuticstrochanteric bursitis; ischial tuberosity bursitis; or the
presence of signiﬁcant and unstable cardiac, pulmonary,
neurologic, hepatic, renal, gastrointestinal, or psychiatric
conditions.
Study Designs
Dose-proportionality Study
This was a single-center, randomized, open-label,
5-treatment, 4-period, crossover study with an
incomplete-block design that was conducted to assess
the dose-proportionality of HYD under naltrexone
blockade. Subjects were randomly assigned to receive
4 of 5 treatments (single dose of HYD 20-, 40-, 60-, 80-,
or 120-mg tablet with 240 mL of water) in a fasted
state, each separated by a washout period of at least
7 days. To minimize opioid-related adverse events (AEs),
each subject received naltrexone hydrochloride 50-mg
tablets with 240 mL of water at 12 hours before and 0,
12, 24, and 36 hours after each dosing of HYD. Blood
samples to determine hydrocodone plasma concentra-
tions were collected from each subject during each of the
treatment periods at the following time points: predose
and at 0.5, 1, 2.5, 4, 6, 8, 10, 12, 14, 16, 18, 24, 30, 36,
48, and 72 hours postdose.
Steady-State Study 1
This was a single-center, open-label, multiple-dose
study conducted to assess the attainment of steady
state of HYD under naltrexone blockade. For 5
consecutive days, each subject was administered a
single HYD 120-mg tablet with 240 mL of water once
daily after an overnight fast of Z8 hours. Fasting
continued until at least 2 hours after study drug
administration, and water was permitted during the
fasting periods. To minimize opioid-related AEs, each
subject received naltrexone hydrochloride 50-mg tab-
lets with 240 mL of water every 12 hours from 12
hours before the ﬁrst dose of HYD through 36 hours
after the last dose. Blood samples to determine hydro-
codone plasma concentrations were collected on days
1 and 5 at the following time points: predose and at 1,
2, 4, 6, 8, 10, 12, 14, 16, 18, and 24 hours postdose of
HYD on that day. In addition, blood samples were
taken at 48 and 72 hours after the ﬁrst dose and at 36,
40, 48, and 72 hours after the last dose.
Steady-State Study 2
This was a single-center, randomized, open-label,
2-treatment, 2-period, multiple-dose, crossover study304to assess the relative bioavailability of HYD 30 mg
every 24 hours compared with IR hydrocodone
bitartrate 7.5 mg/ibuprofen 200 mg‡ every 6 hours
at steady state under naltrexone blockade. Subjects
were randomly assigned to receive, for 3 days, either a
HYD 30-mg tablet once daily or a hydrocodone/
ibuprofen combination tablet every 6 hours, each
with 240 mL of water. There was a minimum 7-day
washout period after the HYD treatment and a 6-
day washout period after the hydrocodone/ibuprofen
combination treatment. HYD was administered after
an overnight fast of Z10 hours, and subjects were
instructed to avoid food for Z4 hours after admin-
istration. Subjects were fasted from food for 2 hours
or more before and after hydrocodone/ibuprofen
administration. To minimize opioid-related AEs, each
subject received naltrexone hydrochloride 50-mg tab-
lets with 240 mL of water every 12 hours beginning at
12 hours before the ﬁrst dose of study drug through
36 hours after the last dose. Blood samples to
determine hydrocodone plasma concentrations were
collected at the following time points: for HYD at
steady state (days 3 or 12); predose; and at 0.5, 1, 2.5,
4, 6, 8, 10, 12, 14, 16, 18, 24, 30, 36, 48, and 72
hours postdose. For hydrocodone bitartrate 7.5 mg/
ibuprofen 200 mg, samples were collected at steady
state (days 3 or 12); predose (morning dose); and at
0.5, 1, 1.5, 2.25, 3, 4, 6, 6.5, 7, 7.5, 8.25, 9, 10, 12,
12.5, 13, 13.5, 14.25, 15, 16, 18, 18.5, 19, 19.5,
20.25, 21, 22, 24, 26, 28, 30, 36, and 42 hours
postdose (morning dose).
Long-Term Effectiveness Study
This was a multicenter, open-label study. All patients
were permitted supplemental pain medications, includ-
ing short-acting opioids, but were required to discon-
tinue all controlled-release or long-acting (ie, ER) opioid
analgesic medications before starting treatment with
HYD. Patients took HYD once daily at a consistent,
patient-chosen time of day without regard to food
intake.
On day 1 of a dose-titration period, opioid-naïve
patients (ie, patients with an incoming opioid dose
equivalent to o5 mg/d of oxycodone) began treat-
ment with HYD 20 mg, and opioid-experienced
patients converted their opioid analgesic regimen to
an appropriate HYD dose (20, 40, 60, or 80 mg onceVolume 38 Number 2
R.P. Kapil et al.daily). For patients who did not achieve adequate
analgesia, doses were up-titrated to the next dose level
after minimum durations of 72 hours of 20, 40, or 60
mg HYD and 120 hours of 80 mg HYD. Dose down-
titration was permitted at any time at the discretion of
the investigator. Patients who achieved stable analge-
sia at the end of the dose-titration period entered the
maintenance period, in which they continued to
receive their end-of-titration-period HYD dose. At
the investigator’s discretion, patients were allowed
dose adjustments of both HYD and supplemental
pain medication during the maintenance period.
Analytical Methods
For each PK study, plasma concentrations of
hydrocodone were quantiﬁed using a validated LS-
MS/MS method. In the dose-proportionality study and
steady-state study 2, hydrocodone was extracted and
eluted with dichloromethane. The eluate was dried by
evaporation and the remaining residue was reconsti-
tuted in acetonitrile/triﬂuoroacetic acid. The ﬁnal
extract was analyzed by HPLC with column-
switching and MS/MS detection using positive ion
electrospray. The lower limit of quantitation for
hydrocodone was 0.1 ng/mL. To evaluate the preci-
sion and accuracy of the assay, quality-control (QC)
samples were prepared from a separate set of stock
solutions for hydrocodone. The QC samples were
analyzed using 2 to 6 replicates during validation.
For the single validation run, the %CV for concen-
trations of hydrocodone ranged from 1.67% to
8.39%, while the absolute percentage of deviation
ranged from 0.185% to 7.97%.
In steady-state study 1, hydrocodone was extracted
into ethyl acetate, and the organic layer was trans-
ferred and dried by evaporation. An aliquot of the
reconstituted extract was injected using an HTS PAL
automated sample injector (CTC Analytics, Zwingen,
Switzerland) and Agilent 1100 Series LC pumps
(Agilent Technologies Inc, Santa Clara, California)
with a BetaSil silica column (Thermo Scientiﬁc Inc,
Rochester, New York) interfaced with an API 4000
mass spectrometer with a TurboIonSpray probe (AB
Sciex, Foster City, California [formerly, MDS Sciex]).
The lower limit of quantitation for hydrocodone was
0.1 ng/mL. To evaluate the precision and accuracy of
the assay, QC samples were prepared from a separate
set of stock solutions for hydrocodone. The QC
samples were analyzed using 6 replicates on eachFebruary 2016day of validation. The %CV for hydrocodone con-
centrations ranged from 1.32% to 3.19%, whereas
the absolute percentage of deviation ranged from
0.333% to 1.00%.
Pharmacokinetics Assessment
For each PK study, plasma concentrations of
hydrocodone were analyzed to determine the PK
parameters for each subject using a noncompartmen-
tal (model-independent) approach. Pharmacokinetic
parameters were calculated using Phoenix WinNonlin
version 6.2.1 (Pharsight Corporation, Mountain
View, California). For the PK analyses, actual blood
sampling times were used.
Dose-proportionality Study
The following parameters were determined: AUClast,
AUC0–1, Cmax, Tmax, t½, and time to the ﬁrst meas-
urable plasma concentration value (Tlag).
Steady-State Study 1
During the ﬁrst dosing interval (day 1, 0–24 hours
after the ﬁrst dose), the following parameters were
determined: AUC0–24, Cmax, and Tmax. At steady state
(day 5), the following parameters were also assessed:
AUCτ,ss; Cmax,ss; Cavg,ss, calculated as AUCτ,ss/Dosing
interval; Cmin,ss; Tmax,ss; and t½,ss. The accumulation
ratio relating steady-state (day 5) exposure to single-
dose (day 1) exposure was deﬁned as AUCτ,ss/AUC0–24,
Cmax,ss/Cmax, and Cmin,ss/Cmin, and the range of
plasma concentration values during steady state rela-
tive to Cavg,ss was deﬁned as (Cmax,ss – Cmin,ss)/Cavg,ss
(percentage ﬂuctuation). At the end of the nth dosing
interval, the following parameters were determined:
minimum observed plasma concentration at the end of
the nth dosing interval (Cmin,nth), and Cmin1, Cmin2,
Cmin3, Cmin4, and Cmin5 concentrations at 24, 48, 72,
96, and 120 hours after the ﬁrst dose, respectively.
Steady-State Study 2
At steady state, the following PK parameters were
determined: AUC24,ss, Cmax,ss, Cavg,ss, Cmin,ss, Tmax,ss, t½,ss,
percentage ﬂuctuation, and percentage swing.
Effectiveness (Pain Assessment over Dosing
Interval)
Long-Term Effectiveness Study
Sustained analgesic effect of HYD over the 24-hour
dosing period was assessed from “pain right now”305
Clinical Therapeuticsscores recorded by the patients in an electronic diary.
Assessments were made before each HYD dosing
(predose) and at 8 PM daily during the dose-titration
period and during the ﬁrst 12 weeks of the maintenance
period. The evening records represented the pain scores
at various times postdose because the study design
allowed patients to take HYD at different times of day.
“Average pain over the last 24 hours” was also
recorded by the patients in an electronic diary at 8
PM daily, using the numeric rating scale listed earlier.
Tolerability Assessment
In the 3 PK studies, tolerability was assessed using
recorded AEs, clinical laboratory results, vital signs,
peripheral oxygen saturation, physical examinations,
and conventional 12-lead ECGs. For the long-term
effectiveness study, safety was assessed using recorded
AEs, clinical laboratory results, vital signs, and 12-
lead ECGs.
Statistical Analysis
Statistical programming and analyses were per-
formed using SAS software (SAS Institute, Cary,
North Carolina).
Dose-proportionality Study
Dose proportionality was assessed by clinical and
statistical review of the descriptive data for HYD. A
power-model approach was used as a sensitivity
method to assess dose proportionality.
Steady-State Study 1
To ascertain when steady state was achieved, the
Cmin value for each of the study drug administrations
was regressed sequentially over time for dosing day
intervals. A 95% CI around the slope of the line was
computed for each regression.
Steady-State Study 2
Relative hydrocodone bioavailability of HYD (test)
was assessed in comparison to hydrocodone/ibuprofen
combination (reference). A mixed-model ANOVA
(SAS PROC MIXED; SAS Institute Inc) was used for
comparing logarithmic-transformed (base e) values
from the test and reference treatments, with ﬁxed
effects for treatment, period, and sequence, and sub-
ject nested within sequence as a random effect. The
90% CIs were estimated for the ratio (test/reference)
of exponentiated least-squares (LS) geometric means.306Long-Term Effectiveness Study
No formal statistical hypothesis testing was per-
formed. All effectiveness data in the long-term study
were summarized using descriptive statistics. Twenty-
four–hour postdose analgesia proﬁle was assessed post
hoc using “pain right now” scores, which were col-
lected in the subject diaries immediately before the daily
HYD dosing and at 8 PM every day during the ﬁrst 3
months of the maintenance period. Mean change in
daily “pain right now” scores (change from predose) at
various times postdose were calculated for patients who
had both predose and postdose scores recorded. Mean
change in “pain right now” scores for each patient on
each postdose hour was averaged so that patients were
equally weighted. If a patient had a dose adjustment
during the maintenance period, data entered during the
day of dose adjustment plus a 5-day window were
excluded. The 24-hour postdose analgesia was also
assessed by comparing 2 main time points of “pain
right now” scores (predose and 12-hour postdose) to
the “average pain over the last 24 hours” scores.RESULTS
Study Populations
Subject baseline characteristics were similar among
the PK studies (Table I). Ages ranged from 20 to 50
years, the majority of subjects were white, about half
were male, and the mean body mass index values were
25 to 26 kg/m2. In the dose-proportionality study, 40
subjects were randomized and dosed. Thirty-one
subjects (77.5%) completed the study, and 9 subjects
(22.5%) discontinued. Reasons for discontinuation
were AEs in 3 subjects (7.5%), subject’s choice in
1 subject (2.5%), loss to follow-up in 1 subject
(2.5%), and administrative reasons in 4 subjects
(10.0%). In steady-state study 1, 27 subjects were
randomized and dosed; 25 subjects (92.6%) com-
pleted the study. One subject (3.7%) discontinued
due to AEs and 1 subject (3.7%) discontinued due to
subject’s choice. In steady-state study 2, 24 subjects
were randomized and dosed; 22 subjects (91.7%)
completed the study, and 2 subjects (8.3%) discon-
tinued due to AEs.
For the HYD long-term effectiveness study, patient
demographics, baseline characteristics, and disposi-
tion have been previously described.15 Brieﬂy, of
922 patients who entered the dose-titration period
and took at least 1 dose of HYD, 728 patientsVolume 38 Number 2
Table I. Baseline characteristics and subject disposition.
Dose-proportionality
Study (n¼ 40)
Steady-state Study
1 (n¼ 27)
Steady-state Study
2 (n¼ 24)
Long-term Effectiveness
Study (Maintenance
Period) (n¼ 728)
Baseline characteristic
Age, mean (range),
y
36 (20–50) 31 (19–48) 33 (21–48) 52 (19–86)
Race, no. (%)
White 26 (65) 22 (82) 17 (71) 607 (83)
Black 14 (35) 3 (11) 6 (25) 110 (15)
Asian 0 2 (7) 1 (4) 6 (1)
Other 0 0 0 5 (1)
Male sex, no. (%) 22 (55) 15 (56) 12 (50) 317 (44)
BMI, mean (SD),
kg/m2
26.0 (2.7) 25.0 (2.6) 25.0 (2.7) 32.1 (7.9)
Subject disposition
Completed study,
no. (%)
31 (78) 25 (93) 22 (92) 410 (56)
Discontinued,
no. (%)
9 (23) 2 (7) 2 (8) 318 (44)
Administrative 4 (10) 0 0 41 (6)
AE 3 (8) 1 (4) 2 (8) 106 (15)
Subject’s choice 1 (3) 1 (4) 0 78 (11)
Loss to follow-up 1 (3) 0 0 30 (4)
Lack of
therapeutic effect
0 0 0 32 (4)
Other 0 0 0 31 (4)
AE ¼ adverse event; BMI ¼ body mass index.
R.P. Kapil et al.achieved stable analgesia and entered the 12-month
maintenance period (Table I). A total of 410 patients
completed the maintenance period. Overall, the demo-
graphic and baseline characteristics were similar
between those who did and those who did not enter
the maintenance period. At baseline, age ranged from
19 to 86 years, and the majority of subjects were
white, with more female patients than male patients.
There were more opioid-experienced patients than
opioid-naïve patients.
Pharmacokinetics
Dose-proportionality Study
Mean plasma concentrations of hydrocodone fol-
lowed a dose-dependent pattern, increasing slowlyFebruary 2016after oral administration of HYD ER tablets, and
reaching a maximum concentration at 14 to 16 hours
postdose. Thereafter, plasma levels declined and re-
mained detectable at 48 hours postdose in most subjects
receiving dose levels Z40 mg (Figure 1). After
normalization to dose, the mean hydrocodone
concentration–time proﬁles were similar, demonstrating
dose proportionality across the dose strengths. The
median Tmax was between 14 and 16 hours across all
dose levels. Mean values for t½ were comparable for all
dose strengths (Table II).
A statistical power model was used as a sensitivity
tool, and the results showed that the slope for the
power model on a logarithmic scale for AUC0–1 was
1.11 (90% CI, 1.02–1.20), which overlaps the307
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Figure 1. Dose-proportionality Study: Mean hy-
drocodone plasma concentration–time
profiles after administration of single-
dose HYD on linear scale (A), on
linear-log scale (B), and as a dose-
normalized profile (C). HYD ¼ hydro-
codone bitartrate once-daily tablets.
Clinical Therapeuticsdose-proportionality limits (90% CI, 0.88–1.12). This
result suggests that there was minimal deviation from
dose proportionality. Similar results were observed for308Cmax. The mean slope for Cmax of hydrocodone was
1.16 and the 90% CI for the slope was 1.08 to 1.24.
The AUC and Cmax increased linearly with doses from
20 to 120 mg. The increase in systemic exposure with
dose was slightly more than dose proportional; how-
ever, this deviation was minimal.Steady-State Study 1
The mean plasma concentrations of hydrocodone
after administration of once-daily dosing of 120 mg
HYD at day 1 and day 5 are shown in Figure 2.
Systemic exposure (AUC and Cmax) to hydrocodone
was similar between day 1 and day 5 (steady state),
and similar minimum plasma concentrations of
hydrocodone were observed at the end of each
dosing interval (Table III). Median Tmax values were
14 hours on both day 1 and day 5 (steady state). After
reaching Cmax, hydrocodone concentrations rapidly
declined, with a mean t½ of 7 hours after the last
dose. The 95% CI of the slope from regression
(0.1452 to 0.0395) included 0, which suggests
that steady state was achieved by the second dose
(day 2) of HYD 120 mg. Minimal accumulation of
hydrocodone was observed after multiple once-daily
dosing of HYD 120 mg for 5 days.Steady-State Study 2
The mean steady-state plasma concentrations of
hydrocodone versus time after administration of HYD
30 mg once daily or hydrocodone/ibuprofen combi-
nation treatment every 6 hours are presented in
Figure 3. At steady state, total exposure (AUC24,ss)
and average hydrocodone plasma concentrations
(Cavg,ss) over a 24-hour period were equivalent for
the 2 treatments (Table IV), with an LS geometric
mean ratio (90% CI) of 93.2% (85.7%–101.4%).
The LS geometric mean steady-state peak exposure
(Cmax,ss) of hydrocodone was lower for HYD (25.4
ng/mL) compared with hydrocodone/ibuprofen
combination treatment (31.0 ng/mL), with an LS
geometric mean ratio (90% CI) of 81.7% (74.9%–
89.2%). The mean percentage ﬂuctuation of hydro-
codone at steady state for HYD every 24 hours (61%)
was less than that of hydrocodone/ibuprofen combi-
nation treatment every 6 hours (96%). The mean t½,ss
values were 8.3 and 4.8 hours, respectively, for HYD
every 24 hours and hydrocodone/ibuprofen combina-
tion treatment every 6 hours.Volume 38 Number 2
Table II. PK parameters of hydrocodone after administration of HYD: Dose-proportionality Study. Data are
given as mean (SD) unless stated otherwise.
HYD Dose
20 mg (n¼ 29) 40 mg (n¼ 31) 60 mg (n¼ 28) 80 mg (n¼ 30) 120 mg (n¼ 29)
Parameter
AUClast, ng  h/mL 281 (127) 618 (250) 1004 (292) 1298 (373) 1759 (671)
AUC0–1, ng  h/mL 284 (128) 622 (252) 1009 (294) 1304 (375) 1787 (679)*
Cmax, ng/mL 14.6 (5.5) 33.9 (11.8) 53.6 (15.4) 69.1 (17.2) 110 (44.1)
Tmax,
† h 16.0 (6.0, 24.0) 16.0 (6.0, 24.0) 14.1 (10.0, 30.0) 16.0 (10.0, 24.0) 14.0 (6.0, 30.0)
t½, h 7.6 (2.6) 7.7 (2.1) 8.1 (2.4) 8.2 (2.4) 8.7 (3.5)
*
Dose proportionality Estimated
Slope
SE Lower 90% CL Upper 90% CL
AUClast, ng  h/mL 1.11 0.0546 1.02 1.21
AUC0–1, ng  h/mL 1.11 0.0549 1.02 1.20
Cmax, ng/mL 1.16 0.0484 1.08 1.24
CL ¼ conﬁdence limit; HYD ¼ hydrocodone bitartrate once-daily tablets; PK, pharmacokinetic.
*n ¼ 28 subjects.
†Median (minimum, maximum).
R.P. Kapil et al.Effectiveness (Pain Assessment over Dosing
Interval)
Long-Term Effectiveness Study
Mean (SD) “average pain scores over the last 24
hours” decreased from 6.4 (1.6) at screening to 3.8140
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Figure 2. Steady-state Study 1: Mean hydrocodone plasm
once-daily HYD 120 mg for 5 days. HYD ¼ hy
February 2016(1.9) at the end of the titration period. The reduction
in mean pain scores was maintained throughout the
12-month maintenance period, with an overall mean
(SD) maintenance period “average pain over the last
24 hours” score of 3.6 (1.8).1596 100 104 108 112 116 120
5   dose (Day 5)th
e (h)
a concentration–time profile after administration of
drocodone bitartrate once-daily tablets.
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Table III. PK parameters of hydrocodone after administration of HYD: Steady-state Study 1. Data are given as
mean (SD) unless stated otherwise.
Parameter
HYD 120 mg (Once Daily on Days 1–5)
Day 1 (n ¼ 24) Day 5* (n ¼ 25) Accumulation Ratio (n ¼ 23)
AUCτ,
ng  h/mL
1541 (332) 1938 (729) 1.3 (0.5)
Cmax, ng/mL 128 (29.6) 135 (49.5) 1.1 (0.3)
Cmin, ng/mL 60.3 (27.6) 63.6 (29.4) 1.1 (0.6)
Tmax,
† h 14.0 (12.0, 23.9) 14 (2.0, 24) –
t½, h – 7.2 (1.9) –
Cmin for Steady State
Cmin, ng/mL‡ Slope from Regression§
Dosing
Interval
Day 1 Dose 1
(n ¼ 24)
Day 2 Dose 2
(n ¼ 26)
Day 3 Dose 3
(n ¼ 25)
Day 4 Dose 4
(n ¼ 25)
Day 5 Dose 5
(n ¼ 25)
Estimate 95% CI
1–5 60.3 (27.6) 59.9 (30.0) 58.9 (31.1) 54.2 (38.9) 63.6 (29.4) 0.0529 (0.1452 to
0.0395)
HYD ¼ hydrocodone bitartrate once-daily tablets; PK ¼ pharmacokinetic.
*Steady state.
†Median (minimum, maximum).
‡Mean (SD) calculated and reported in original scale.
§The slope estimate (95% CI) was derived from a regression model: ln(Cmin) ¼ Day þ Subject þ Random error,
where ln(Cmin) was natural logarithm transformed before analysis, day was a continuous variable, and subject was a
random effect.
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Figure 3. Steady-state Study 2: Mean plasma
concentrations of hydrocodone versus
time at steady state (full analysis
population). HYD ¼ hydrocodone
bitartrate once-daily tablets; IR ¼
immediate release.
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310In the maintenance period, the mean (SD) “pain right
now” scores were similar at predose (3.6 [1.9]; n¼ 725)
and 12 hours postdose (3.4 [1.9], n¼ 592) (Figure 4).
Mean changes in “pain right now” scores from predose
(corresponding with “trough” hydrocodone systemic
exposure) to various time points postdose during the
maintenance period are shown in Figure 5. Throughout
the 24-hour dosing interval, the mean change in “pain
right now” scores recorded at postdose time points
hovered over 0, indicating no difference in postdose
pain scores from that recorded immediately before each
daily dosing. In other words, the pain control was
consistent during the 24-hour dosing interval.
Although patients were allowed to use supplemen-
tal pain medications, including short-acting (but not
long-acting or controlled-release) opioids, the use of
short-acting opioids was substantially reduced on
conversion to HYD and remained at this reduced
level through 12 months of HYD treatment. TheVolume 38 Number 2
Table IV. PK parameters of hydrocodone after administration of HYD: Steady-state Study 2. Data are given as
mean (SD) unless stated otherwise.
Parameter HYD (30 mg q24h for 3 d) (n¼22)
Hydrocodone Bitartrate 7.5 mg/
Ibuprofen 200 mg (q6h for 3 d)
(n¼ 23)
AUC24,ss, ng  h/mL 443 (128) 470 (111)
Cmax,ss, ng/mL 26.4 (7.4) 31.6 (6.6)
Tmax,ss,
* h 16.0 (1.0, 24.0) 1.5 (0.50, 19.5)
Cavg,ss, ng/mL 18.4 (5.3) 19.6 (4.6)
Cmin,ss, ng/mL 16.7 (5.2) 13.4 (4.0)
t½,ss, h 8.3 (2.4) 4.8 (0.6)
% Fluctuation 60.5† (30.2) 96.3 (26.8)
% Swing 88.3† (85.8) 148.2 (58.7)
LS Geometric Mean‡
Parameter
HYD (30 mg
q24h for 3 d)
(Test; n ¼ 22)
Hydrocodone Bitartrate 7.5 mg/
Ibuprofen 200 mg (q6h for 3 d)
(Reference; n ¼ 23)
Estimated Mean
Ratio (%)§ (Test/
Reference)
90% CI for Ratio‖
AUC24,ss, ng  h/mL 427 458 93.2 (85.7–101.4)
Cavg,ss, ng/mL 17.8 19.1 93.2 (85.7–101.4)
Cmax,ss, ng/mL 25.4 31.0 81.7 (74.9–89.2)
HYD ¼ hydrocodone bitartrate once-daily tablets; LS ¼ least squares; PK ¼ pharmacokinetic.
*Median (minimum, maximum).
†n ¼ 18.
‡Least squares mean from ANOVA. Natural log(ln) metric means were calculated by transforming the natural logarithmic
means back to the linear scale (ie, geometric means).
§Ratio of metric means for ln-transformed metrics (expressed as a percentage). Ln-transformed ratio was transformed back
to linear scale.
‖The 90% CI for ratio of metric means (expressed as a percentage). Ln-transformed conﬁdence limits were transformed back
to linear scale.
R.P. Kapil et al.average daily dose of HYD remained stable during the
maintenance period.15
Tolerability
Dose-proportionality Study
There were no deaths or serious AEs (SAEs).
Three subjects discontinued from the study due to
the following AEs: dyspnea and urticaria, hypoesthe-
sia, and hematochezia. Overall, 21 of 40 subjects
(53%) experiencedZ1 AE. The number of treatment-
related AEs was similar across the 5 treatments.
All AEs resolved by the end of the study. With the
exception of 6 AEs of moderate severity in 3 sub-
jects, all AEs reported during this study were mild.February 2016Moderate AEs consisted of nausea, vomiting, dyspha-
gia, and dyspnea. The AEs experienced by Z2
subjects in any treatment group consisted of abdomi-
nal pain, nausea, dizziness, headache, and somno-
lence.
Steady-State Study 1
There were no deaths or SAEs. One subject dis-
continued from the study due to AEs of headache,
nausea, vomiting, and dizziness. The AEs experienced
by Z2 subjects consisted of dizziness, dysgeusia,
headache, medical device site reaction, myalgia,
nausea, paresthesia, scratch, vessel puncture site pain,
and vomiting. All AEs were of mild or moderate311
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Figure 4. Long-term Effectiveness Study: Mean
“pain right now” scores recorded im-
mediately before each HYD daily dose
and at 12 hours postdose, and mean
“average pain over last 24 hours”
score during the maintenance
period.15
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Figure 5. Long-term Effectiveness Study: Mean
changes in “pain right now” scores
from immediately before each daily
dose to various time points postdose
during the maintenance period.15 n¼
15–587. *Score at 24 hours ¼ score at
0 hour. The data between 20 and 23
hours postdose are not shown because
insufficient data were collected at those
times; the majority of patients dosed
themselves in the morning and were
resting at these postdose times.
Clinical Therapeuticsintensity, and all AEs were resolved by the end of
the study.
Steady-State Study 2
There were no deaths or SAEs. Two subjects
discontinued from the study, 1 due to hematemesis
and 1 due to vomiting. The majority of AEs were
mild, with the exception of 9 treatment-emergent AEs
in 2 subjects (nausea, vomiting, hematemesis, and
abdominal pain) that were moderate in severity.
In all 3 PK studies, no clinically signiﬁcant changes
were observed in clinical laboratory values, vital
sign and peripheral oxygen saturation measurements,
or ECG results for any of the treatments studied. The
administration of HYD ER tablets was well tolerated in
healthy adult subjects under naltrexone blockade.
Long-Term Effectiveness Study
The majority of the treatment-emergent AEs reported
were mild or moderate in severity and were characteristic
of opioid treatment.16 Among the 922 patients in the
safety assessment population, there was 1 death and 12
SAEs that were considered to be related to HYD. There
were no new or unexpected safety concerns. Analysis of
clinical laboratory tests; vital sign measurements; and
ECG intervals, rhythm, and morphology did not show
any clinically meaningful changes. In addition, use of
supplemental opioid medication decreased during the312titration period and remained stable during the
maintenance period of the trial; use of nonopioid pain
medication either diminished or remained unchanged
during the maintenance treatment with HYD in the
long-term effectiveness study.15DISCUSSION
ER HYD tablets were formulated to provide a steady-
state PK proﬁle that maintains efﬁcacy throughout the 24-
hour dosing interval. The PK attributes of HYD demon-
strated dose proportionality across the 20 to 120-mg
range of HYD tablet strengths. After once-daily dosing of
HYD 120 mg, consistent plasma hydrocodone concen-
trations over the 24-hour dosing interval were observed
with minimal accumulation. Steady state was achieved
after 2 HYD doses. The comparison of steady-state peak-
to-trough ﬂuctuation of HYD administered once daily
versus IR hydrocodone/ibuprofen administered every 6
hours provides an assessment of the ability of HYD to
maintain consistent plasma concentrations over a 24-hour
dosing interval. At the same total daily dose, mean peak-
to-trough hydrocodone ratio at steady state was lower forVolume 38 Number 2
R.P. Kapil et al.HYD (1.6) than for IR hydrocodone/ibuprofen (2.4),
while total systemic hydrocodone exposures (AUC) were
similar, suggesting bioequivalence of the 2 dosing regi-
mens. Predictable PK and a broad range of HYD tablet
strengths (20, 30, 40, 60, 80, 100, and 120 mg) provide
prescribers the ability of convenient dose titration to meet
individual patient analgesia requirements.
ER opioid formulations that provide sustained
analgesia with once-daily dosing are important for
the treatment of chronic pain in patients. However,
end-of-dose failure, a phenomenon often reported for
IR analgesics,7 may occur with ER opioids. End-of-
dose failure occurs when the analgesic effects of the
ER medication wear off sooner than the expected
duration of action, and pain returns before the next
scheduled dose of medication. Inadequate doses, fail-
ure of the formulation to deliver sustained analgesia as
intended, or nonadherence to the dosing regimens
may contribute to end-of-dose failure. The ability of
HYD to provide sustained analgesia over the 24-hour
dosing interval in patients with chronic pain was
evaluated prospectively in the long-term study.
Analysis of “pain right now” scores showed that, on
average, the “pain right now” score collected immediately
before each daily dosing, when end-of-dose failure would
have occurred, was the same as the “pain right now”
score 12 hours postdose (approaching the mean Tmax).
Both “pain right now” scores were similar to the assess-
ment of pain over the entire 24-hour period (“average
pain over the last 24 hours” score). The “average pain
over the last 24 hours” score was the primary assessment
of pain control over the long-term HYD treatment,
which, in this study, exhibited substantial reduction and
was maintained for up to 12 months, with limited need
for dose adjustment. Similarly, with regard to the change
in “pain right now” scores throughout the 24-hour
dosing interval, patients reported no difference in pain
level at various postdose times compared with predose.
All pain scores were measures of pain control for the
patients receiving HYD as well as any supplemental
analgesics. The use of supplemental analgesics decreased
substantially on commencement with HYD and remained
stable at the lower levels for up to 12 months, indicating
that HYD provided adequate analgesia without the
need for adjuvant medications.15 Together, HYD
demonstrated sustained analgesia over a 24-hour period
that translated into long-term effectiveness of this treat-
ment. Sustained analgesia over a 24-hour period (as seen
in the current long-term effectiveness study) at steadyFebruary 2016state after once-daily dosing is consistent with the
sustained plasma concentrations of hydrocodone over
the 24-hour dosing interval observed in the PK studies.
The mean plasma concentrations from the once-daily
dose were consistently higher than the trough levels from
IR QID dosing at steady state, suggesting that the average
plasma concentration (Cavg, equal to AUC0–1/24) is
correlated with analgesia. These observations of mean
steady-state concentrations are consistent with demon-
strations of efﬁcacy after once-daily dosing of other
opioids when compared with IR formulations.17,18
A limitation of this integrated analysis is that the PK
studies and the long-term effectiveness study differed in
study design and participants. For example, in the PK
studies, subjects were healthy, younger individuals; the
studies lasted for a few days; and the subjects were
administered HYD in the fasting condition while
conﬁned to the study site. In the long-term effectiveness
study, enrolled patients were older with chronic pain,
the study lasted more than a year, and participants
took HYD without regard to meals. However, the
subjects in all of these studies were administered HYD
once per 24 hours. A separate PK study comparing the
PK properties between young (20–45 years) and elderly
(465 years) volunteers showed no clinically mean-
ingful differences in Cmax (16%) and AUC (15%) of
hydrocodone between the 2 study populations.14CONCLUSIONS
Results from pharmacokinetic studies showed that HYD
provided consistent plasma hydrocodone concentrations
after once-daily dosing, and results from a 12-month
open-label study showed that once-daily HYD provided
sustained analgesia over the 24-hour dosing interval.
Compared with IR hydrocodone, HYD at the same total
daily dose exhibited similar bioavailability, but with lower
maximum concentrations and higher minimum concen-
trations at steady state. Across all studies described in this
report, HYD administration was generally well tolerated;
the majority of AEs reported were those associated with
opioid treatment and were mostly mild to moderate in
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